Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Thomas Mckearn Insider Profile
4 Followers
Thomas Mckearn, President, R&D at Traws Pharma, holds 100.22K shares in Advaxis (Ticker: ADXS), holds 3.33K shares in Traws Pharma (Ticker: TRAW). Most recently, Thomas Mckearn Sold ― shares of Advaxis on Dec 21, 2016 for an estimated value of 99.51K.
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
+14.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Thomas Mckearn
Thomas Mckearn's Trading History
Traws Pharma
Jul 30, 2013
President, R&D
Informative Buy
49.99K
$2.17K
Advaxis
Dec 21, 2016
Director
Informative Sell
99.51K
$62.64K
List of latest transactions for each holding click on a transaction to see Thomas Mckearn's performance on stock
You May Also Like
Thomas Mckearn insider profile FAQ
What is the percentage of profitable transactions made by Thomas Mckearn?
The percentage of profitable transactions made by Thomas Mckearn is 33%.
What is the average return per transaction made by Thomas Mckearn?
The average return per transaction made by Thomas Mckearn is 14.60%.
What stocks does Thomas Mckearn hold?
Thomas Mckearn holds: TRAW, ADXS stocks.
What was Thomas Mckearn’s latest transaction?
Thomas Mckearn latest transaction was an Informative Sell of $99.51K.
What was Thomas Mckearn's most profitable transaction?
Thomas Mckearn’s most profitable transaction was an Informative Sell of ADXS stock on December 21, 2016. The return on the trade was 62.30%.
What is Thomas Mckearn's role in Traws Pharma?
Thomas Mckearn's role in Traws Pharma is President, R&D.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.